Alzheimer's biotech Alzheon nets $50M Series D; Evelo puts PhI atopic dermatitis program on hold
A Framingham, MA-based biotech has some new cash to play with.
Alzheon announced Thursday morning it has completed a $50 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
